Sequential Adjuvant Chemo-Radiotherapy With Vs. Without Erythropoeitin For Patients With High-Risk Cervical Cancer-Second Analysis Of A Prospective, Randomized, Open And Controlled AGO- AND Sequential Adjuvant Chemo-Radiotherapy With Vs. Without Erythropoeitin For Patients With High-Risk Cervical Cancer-Second Analysis Of A Prospective, Randomized, Open And Controlled AGO- And NOGGO-Intergroup Study
Reviewer: Roberto Santiago, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 19 de mayo del 2002
Presenter: Jens U Blohmer
Presenter's Affiliation: Humboldt University, Berlin, Germany
Type of Session: Poster
- The aim of the study was to compare the disease-free survival achieved by an adjuvant sequential chemoradiotherapy regimen with vs. without Erythropoeitin (EPO) for patients with high-risk cervical cancer
- The second endpoints of the study included toxicity, number of transfusions, quality of life, and survival
Materials and Methods
- All patients underwent a radical hysterectomy and adjuvant chemotherapy and radiation therapy was recommended postoperatively
- Patients were stratified according to pelvic nodes (pN0 vs. pN1), stage (Ib, IIa vs. IIb), and resection (R0 vs. R1)
- Patients were randomized to sequential chemotherapy followed by radiotherapy with EPO or without EPO
- All patients received 4 cycles (q21d) of ifosphamide (1.6 mg/m2, d1-3), carboplatin (AUC 4, d1) and subsequent radiotherapy (5 weekly fractions of 1.8-2 Gy up to 50-50.5 Gy)
- EPO arm: EPO 10,000 IU three times a week + oral iron supplements up to a Hb target value of 13 g/dl
- No EPO arm: only transfusions were allowed
- 128 patients from 63 clinics were randomized to each arm between 01/1999 and 03/2001
- EPO was given as planned in about half of the patients analyzed in the EPO-arm
- The EPO-application was stopped in 33% of patients because a Hb > 14g/dl was achieved
- The EPO dose was reduced (10.000 IE/3x/week) in 8% of patients because a Hb > 13 g/dl was achieved
- The median doses of carboplatin and ifosphamide (in both arms) were AUC 4 and 1.6 g/m2, respectively
- 84% of the patients completed the 4 cycles of chemotherapy
- Median radiation dose was 50.4 Gy
- Median follow-up was 64.5 weeks
- There was a significantly higher recurrence-free survival rate in the EPO-arm (89% vs. 78%, p=0.04)
- There was a significant reduction of grade 2 anemia (20% vs. 51%, p=0.01) and in the number of red blood cell (no transfusion required: 91% vs. 67%; p=0.0046) as well as platelet transfusions (p=0.0025) in the EPO-arm
- Adjuvant sequential chemoradiotherapy with EPO support in patients with high-risk cervical cancer was demonstrated to be easily tolerated and associated to few treatment interruptions
- After a short follow-up period, support with EPO appeared to afford a lower rate of recurrences
- It is plausible that the benefit seen is due to re-oxygenation of hypoxic tumors but further research is needed to confirm this hypotesis.
- If these findings are confirmed with further follow-up routine EPO support could become a standard component of chemoradiotherapy for cervical cancer.
Oncolink's ASCO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology.
ASTRO: Radiotherapy Found to Be Beneficial in Melanoma
Jan 28, 2015 - In melanoma patients at high risk of regional relapse after lymphadenectomy, adjuvant radiotherapy may significantly improve regional control, according to research presented this week at the 51st Annual Meeting of the American Society for Radiation Oncology, held from Nov. 1 to 5 in Chicago.
Frequently Asked Questions
National Cancer Institute
I Wish You Knew
How cancer patients have changed my life
Blogs and Web Chats
OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.
Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!